PMID- 19819280
OWN - NLM
STAT- MEDLINE
DCOM- 20100121
LR  - 20231213
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 71
IP  - 1
DP  - 2010 Jan
TI  - Identification of a microRNA signature in dendritic cell vaccines for cancer 
      immunotherapy.
PG  - 67-73
LID - 10.1016/j.humimm.2009.10.001 [doi]
AB  - Dendritic cells (DCs) exposed to tumor antigens followed by treatment with 
      T(h)1-polarizing differentiation signals have paved the way for the development 
      of DC-based cancer vaccines. Critical parameters for assessment of the optimal 
      functional state of DCs and prediction of the vaccine potency of activated DCs 
      have in the past been based on measurements of differentiation surface markers 
      like HLA-DR, CD80, CD83, CD86, and CCR7 and the level of secreted cytokines like 
      interleukin-12p70. However, the level of these markers does not provide a 
      complete picture of the DC phenotype and may be insufficient for prediction of 
      clinical outcome for DC-based therapy. We therefore looked for additional 
      biomarkers by investigating the differential expression of microRNAs (miRNAs) in 
      mature DCs relative to immature DCs. A microarray-based screening revealed that 
      12 miRNAs were differentially expressed in the two DC phenotypes. Of these, four 
      miRNAs, hsa-miR-155, hsa-miR-146a, hsa-miR-125a-5p, and hsa-miR-29a, were 
      validated by real-time polymerase chain reaction and northern blotting. The 
      matured DCs from 12 individual donors were divided into two groups of highly and 
      less differentiated DCs, respectively. A pronounced difference at the level of 
      miRNA induction between these two groups was observed, suggesting that 
      quantitative evaluation of selected miRNAs potentially can predict the 
      immunogenicity of DC vaccines.
FAU - Holmstrom, Kim
AU  - Holmstrom K
AD  - Bioneer A/S, Horsholm, Denmark. kho@bioneer.dk
FAU - Pedersen, Ayako Wakatsuki
AU  - Pedersen AW
FAU - Claesson, Mogens Helweg
AU  - Claesson MH
FAU - Zocca, Mai-Britt
AU  - Zocca MB
FAU - Jensen, Simon Skjode
AU  - Jensen SS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Antigens, CD)
RN  - 0 (CCR7 protein, human)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Genetic Markers)
RN  - 0 (Immunoglobulins)
RN  - 0 (MIRN155 microRNA, human)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (MicroRNAs)
RN  - 0 (Receptors, CCR7)
SB  - IM
MH  - Antigens, CD/analysis/genetics
MH  - Cancer Vaccines/*genetics/*immunology
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Dendritic Cells/chemistry/cytology/*immunology
MH  - Flow Cytometry
MH  - Gene Expression Regulation
MH  - Genetic Markers
MH  - Humans
MH  - Immunoglobulins/analysis/genetics
MH  - Immunotherapy
MH  - Membrane Glycoproteins/analysis/genetics
MH  - MicroRNAs/*analysis/genetics
MH  - Neoplasms/genetics/*immunology/*therapy
MH  - Receptors, CCR7/analysis/genetics
MH  - CD83 Antigen
EDAT- 2009/10/13 06:00
MHDA- 2010/01/22 06:00
CRDT- 2009/10/13 06:00
PHST- 2009/06/03 00:00 [received]
PHST- 2009/09/22 00:00 [revised]
PHST- 2009/10/02 00:00 [accepted]
PHST- 2009/10/13 06:00 [entrez]
PHST- 2009/10/13 06:00 [pubmed]
PHST- 2010/01/22 06:00 [medline]
AID - S0198-8859(09)00608-9 [pii]
AID - 10.1016/j.humimm.2009.10.001 [doi]
PST - ppublish
SO  - Hum Immunol. 2010 Jan;71(1):67-73. doi: 10.1016/j.humimm.2009.10.001.